Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | IRX-2 |
| Trade Name | |
| Synonyms | Citoplurikin |
| Drug Descriptions |
Citoplurikin (IRX-2) is an immunotherapeutic comprising a mixture of the cytokines IL-2, IL-1beta, IFN-gamma, TNF-alpha, IL-8, IL-6, and GM-CSF, which may increase anti-tumor immune response (PMID: 19180118, PMID: 23408925, PMID: 32738599, PMID: 31831558). |
| DrugClasses | |
| CAS Registry Number | 951209-71-5 |
| NCIT ID | C53396 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cyclophosphamide + Doxorubicin + IRX-2 + Paclitaxel + Pembrolizumab | Cyclophosphamide Doxorubicin IRX-2 Paclitaxel Pembrolizumab | 0 | 1 |
| Cyclophosphamide + Indomethacin + IRX-2 | Cyclophosphamide IRX-2 Indomethacin | 0 | 1 |
| Cyclophosphamide + IRX-2 + Nivolumab | Cyclophosphamide IRX-2 Nivolumab | 0 | 3 |
| Cyclophosphamide + IRX-2 + Pembrolizumab | Cyclophosphamide IRX-2 Pembrolizumab | 0 | 1 |
| IRX-2 | IRX-2 | 0 | 0 |
| IRX-2 + Nivolumab | IRX-2 Nivolumab | 0 | 0 |
| IRX-2 + Pembrolizumab | IRX-2 Pembrolizumab | 0 | 0 |